Siltuximab administration results in spurious <scp>IL</scp>‐6 elevation in peripheral blood-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Siltuximab administration results in spurious IL‐6 elevation in peripheral blood

Published:2023-10-23 Issue:1 Volume:99 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Mango Natalie A.¹^ORCID,Pierson Sheila K.¹^ORCID,Sarmiento Bustamante Mateo¹^ORCID,Brandstadter Joshua D.²,van Rhee Frits³^ORCID,Fajgenbaum David C.¹^ORCID

Affiliation:

1. Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

2. Division of Hematology/Oncology, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

3. Myeloma Center, Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences Little Rock Arkansas USA

Funder

EUSA Pharma

Janssen Pharmaceuticals

National Heart, Lung, and Blood Institute

U.S. Food and Drug Administration

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27132

Reference6 articles.

1. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

2. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

3. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

4. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy

5. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy;Blood Vessels, Thrombosis & Hemostasis;2024-06

2. Idiopathic multicentric Castleman disease and connective tissue disorder successfully treated by siltuximab: a pediatric case report;Translational Pediatrics;2024-05

3. Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy;Frontiers in Immunology;2024-02-29

4. Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy;2024-01-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3